DK1280541T4 - Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse eller behandling af fordøjelsesforstyrrelser - Google Patents

Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse eller behandling af fordøjelsesforstyrrelser

Info

Publication number
DK1280541T4
DK1280541T4 DK01934089.2T DK01934089T DK1280541T4 DK 1280541 T4 DK1280541 T4 DK 1280541T4 DK 01934089 T DK01934089 T DK 01934089T DK 1280541 T4 DK1280541 T4 DK 1280541T4
Authority
DK
Denmark
Prior art keywords
hydrogenotrophic
prevention
treatment
digestive disorders
acetogenic
Prior art date
Application number
DK01934089.2T
Other languages
English (en)
Other versions
DK1280541T3 (da
Inventor
Michel Renaud
Annick Bernalier
Original Assignee
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1280541(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agronomique Inst Nat Rech filed Critical Agronomique Inst Nat Rech
Application granted granted Critical
Publication of DK1280541T3 publication Critical patent/DK1280541T3/da
Publication of DK1280541T4 publication Critical patent/DK1280541T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
DK01934089.2T 2000-05-11 2001-05-11 Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse eller behandling af fordøjelsesforstyrrelser DK1280541T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006009A FR2808689B1 (fr) 2000-05-11 2000-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
PCT/FR2001/001426 WO2001085187A1 (fr) 2000-05-11 2001-05-11 Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs

Publications (2)

Publication Number Publication Date
DK1280541T3 DK1280541T3 (da) 2006-07-17
DK1280541T4 true DK1280541T4 (da) 2010-07-05

Family

ID=8850107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01934089.2T DK1280541T4 (da) 2000-05-11 2001-05-11 Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse eller behandling af fordøjelsesforstyrrelser

Country Status (13)

Country Link
US (2) US7749494B2 (da)
EP (1) EP1280541B2 (da)
JP (1) JP5183848B2 (da)
AT (1) ATE322902T1 (da)
AU (2) AU2001260400B2 (da)
CA (1) CA2411563C (da)
CY (1) CY1107467T1 (da)
DE (1) DE60118723T3 (da)
DK (1) DK1280541T4 (da)
ES (1) ES2262650T5 (da)
FR (1) FR2808689B1 (da)
PT (1) PT1280541E (da)
WO (1) WO2001085187A1 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4618970B2 (ja) * 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
US7935334B2 (en) * 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US20060008511A1 (en) * 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
PL2072053T3 (pl) 2007-12-21 2013-02-28 Gervais Danone Sa Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium
EP2130543A1 (en) 2008-06-05 2009-12-09 Compagnie Gervais Danone Method for decreasing borborygmi by administering a bifidobacterium bacteria
SI3564357T1 (sl) 2010-02-01 2022-09-30 Rebiotix, Inc. Bakterioterapija Clostridium Difficile colitisa
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
JP2013537531A (ja) 2010-08-04 2013-10-03 トーマス・ジュリアス・ボロディ 糞便細菌叢移植のための組成物ならびにそれを作製および使用する方法ならびにそれを送達するためのデバイス
HK1253538A1 (zh) * 2010-08-04 2019-06-21 Borody Thomas J 用於糞便菌群植入的組合物及其製備和使用方法
KR101805873B1 (ko) * 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
AU2012225305B2 (en) 2011-03-09 2017-06-08 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2785828B1 (en) 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
PL3003330T3 (pl) 2013-06-05 2019-03-29 Rebiotix, Inc. Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
CN108138122B (zh) 2014-12-23 2021-09-21 4D制药研究有限公司 免疫调控
DK3193901T3 (da) 2014-12-23 2018-05-28 4D Pharma Res Ltd Pirinpolypeptid og immunmodulation
MX2017010859A (es) * 2015-02-27 2018-08-15 White Dog Labs Inc Metodo de fermentacion mixotrofica para poducir acetona, isopropanol, acido butirico y otros bioproductos, y mezclas de los mismos.
AU2016259871B2 (en) 2015-05-11 2020-04-16 Mybiotics Pharma Ltd Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PL3307289T3 (pl) 2015-06-09 2022-01-17 Rebiotix, Inc. Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203223A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
DK3307288T3 (da) 2015-06-15 2019-10-07 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
PL3209310T3 (pl) 2015-11-20 2018-08-31 4D Pharma Research Limited Kompozycja zawierająca szczepy bakteryjne
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) * 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
SG11201810428PA (en) 2016-05-25 2018-12-28 Mybiotics Pharma Ltd Composition and methods for microbiota therapy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) * 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
KR20200019882A (ko) 2017-05-22 2020-02-25 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
CA3064773A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
ES2917415T3 (es) 2017-06-14 2022-07-08 4D Pharma Res Ltd Composiciones que comprenden una cepa bacteriana
JP6884889B2 (ja) 2017-06-14 2021-06-09 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
KR20210021461A (ko) 2018-06-19 2021-02-26 4디 파마 리서치 리미티드 살아있는 바이오치료 제품을 포함하는 제형
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
SG11202100228XA (en) 2018-07-16 2021-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
KR20220006517A (ko) 2019-05-10 2022-01-17 4디 파마 리서치 리미티드 세균 균주를 포함하는 조성물
US20220331376A1 (en) * 2019-09-05 2022-10-20 White Dog Labs Mixotrophic probiotic compositions and uses thereof in the treatment of bloating
EP3839039A1 (en) 2019-12-16 2021-06-23 4D Pharma Research Limited Providing bacterial biomass with improved storage stability
TW202220639A (zh) 2020-08-06 2022-06-01 英商４Ｄ製藥有限公司 凍乾方法
KR20230112700A (ko) 2020-11-26 2023-07-27 4디 파마 레온, 에스.엘.유. 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
AUPM823094A0 (en) 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
AUPN698495A0 (en) * 1995-12-06 1996-01-04 Pharma Pacific Pty Ltd Improved therapeutic formulation and method
CA2249189A1 (en) * 1996-03-20 1997-09-25 The University Of New South Wales Alteration of microbial populations in the gastrointestinal tract
SE511524C2 (sv) 1997-06-02 1999-10-11 Essum Ab Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier
DE19826928A1 (de) * 1998-06-17 1999-12-23 Novartis Consumer Health Gmbh Arzneimittel, lebensfähige anaerobe Bakterien enthaltend, die die Sulfatreduktion sulfatreduzierender Bakterien hemmen
WO2000010581A1 (fr) * 1998-08-20 2000-03-02 Miyarisan Pharmaceutical Co., Ltd. Medicaments comprenant une combinaison d'une bacterie produisant de l'acide butyrique, et d'un constituant d'acide biliaire

Also Published As

Publication number Publication date
US7749494B2 (en) 2010-07-06
CA2411563C (fr) 2012-12-11
EP1280541A1 (fr) 2003-02-05
AU2001260400B2 (en) 2006-10-26
CA2411563A1 (fr) 2001-11-15
ATE322902T1 (de) 2006-04-15
JP5183848B2 (ja) 2013-04-17
US20030147858A1 (en) 2003-08-07
EP1280541B1 (fr) 2006-04-12
EP1280541B2 (fr) 2010-03-17
FR2808689A1 (fr) 2001-11-16
DE60118723T3 (de) 2010-09-30
PT1280541E (pt) 2006-06-30
JP2004501095A (ja) 2004-01-15
WO2001085187A1 (fr) 2001-11-15
ES2262650T3 (es) 2006-12-01
FR2808689B1 (fr) 2004-09-03
ES2262650T5 (es) 2010-06-28
CY1107467T1 (el) 2012-12-19
DE60118723D1 (de) 2006-05-24
AU6040001A (en) 2001-11-20
US20100316617A1 (en) 2010-12-16
DK1280541T3 (da) 2006-07-17
DE60118723T2 (de) 2006-12-28

Similar Documents

Publication Publication Date Title
DK1280541T3 (da) Anvendelse af hydrogenotrofe, acetogene stammer til forebyggelse af eller behandling af fordöjelsesforstyrrelser
ATE413386T1 (de) Ppar-gamma modulatoren
NO20061736L (no) Krystallform av epotilon B
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
HUP0101128A2 (hu) Lipáz enzimeket gátló polimerek alkalmazása elhízás elleni gyógyszerként
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ME00578A (en) Use of gastrointestinal lipase inhibitors
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
MX2007011381A (es) Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion.
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
ATE418613T1 (de) Antimikrobielle zusammensetzungen
SE0203817D0 (sv) New composition
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner